Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at Wall Street Zen

Wall Street Zen started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) in a research note released on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.

SGMO has been the topic of a number of other reports. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Royal Bank of Canada reiterated a "sector perform" rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Barclays cut their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Finally, Truist Financial cut their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $4.50.

Sangamo Therapeutics Trading Down 4.3%

NASDAQ SGMO traded down $0.02 during trading hours on Thursday, reaching $0.45. The company had a trading volume of 5,231,173 shares, compared to its average volume of 8,758,739. The stock has a 50-day moving average of $0.67 and a 200 day moving average of $1.23. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The stock has a market capitalization of $105.65 million, a P/E ratio of -0.60 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The business had revenue of $6.44 million for the quarter, compared to analysts' expectations of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. As a group, sell-side analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. E Fund Management Co. Ltd. purchased a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $25,000. JPMorgan Chase & Co. increased its stake in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $28,000. Finally, Captrust Financial Advisors purchased a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $30,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.